gatifloxacin has been researched along with isoniazid in 36 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 18 (50.00) | 29.6817 |
2010's | 16 (44.44) | 24.3611 |
2020's | 2 (5.56) | 2.80 |
Authors | Studies |
---|---|
Pavana, RK; Sriram, D; Thirumurugan, R; Yogeeswari, P | 1 |
Kumar, RR; Perumal, S; Senthilkumar, P; Sriram, D; Yogeeswari, P | 1 |
China, A; Dinakaran, M; Nagaraja, V; Senthilkumar, P; Sriram, D; Yogeeswari, P | 3 |
Banerjee, D; China, A; Devakaram, RV; Dinakaran, M; Nagaraja, V; Senthilkumar, P; Sriram, D; Yogeeswari, P | 1 |
Bitting, C; Gruppo, V; Johnson, CM; Lenaerts, AJ; Marietta, KS; Orme, IM; Woolhiser, L | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Ackerman, M; Cynamon, MH; Pucci, MJ; Shoen, CM; Thanassi, JA | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Baulard, AR; Crauste, C; Déprez, B; Flipo, M; Villemagne, B; Willand, N | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Feng, LS; Gao, C; Hu, YQ; Lv, ZS; Wu, X; Xu, Z; Zhang, S; Zhao, F | 1 |
Cheng, XW; Fan, YL; Feng, LS; Wu, JB; Zhang, FZ | 1 |
Bai, L; Deng, JL; Gao, F; Lv, ZS; Wang, Y; Xu, Z; Zhang, F; Zhao, SJ | 1 |
Chen, L; Chen, Z; Fan, Y; Gao, F; Lu, G; Ma, L | 1 |
Dhawan, S; Girase, PS; Karpoormath, R; Kumar, V; Palkar, MB; Shinde, SR | 1 |
Alvirez-Freites, EJ; Carter, JL; Cynamon, MH | 1 |
Cynamon, MH; DeStefano, MS; Monica, BJ; Shoen, CM; Sklaney, MR; Slee, AM | 1 |
Kubendiran, G; Mitchison, DA; Paramasivan, CN; Sulochana, S; Venkatesan, P | 1 |
Kubendiran, G; Mitchison, DA; Paramasivan, CN; Sulochana, S | 1 |
Cynamon, M; Shoen, C; Sklaney, MR | 1 |
Fourie, PB; Horton, J; Kanyok, TP; McIlleron, H; Norman, J; Smith, PJ | 1 |
Krinke, GJ; Wells, MY | 1 |
Allen, J; Coleman, DJ; Davies, GR; Fourie, B; Kanyok, T; Levin, J; Lienhardt, C; Mitchison, DA; Mthiyane, T; Reddy, C; Rustomjee, R; Sirgel, FA; Sturm, AW | 1 |
Jhamb, SS; Singh, PP | 1 |
Cai, HL; Chen, YC; Fang, PF; Gao, W; Li, HD; Liu, YP; Tan, QY; Xu, P; Zhang, F; Zhang, WY; Zhu, RH | 1 |
Ambrose, PG; Bhavnani, SM; Caws, M; Chau, TT; Dung, NT; Farrar, J; Hammel, JP; Hien, TT; Kulawy, R; Mai, PP; Reynolds, DK; Thwaites, GE; Török, ME; Van Wart, SA | 1 |
Bah-Sow, O; Gninafon, M; Horton, J; Lienhardt, C; Lo, MB; McIlleron, H; Merle, CS; Olliaro, PL; Rustomjee, R; Simonsson, US; Smith, P; Smythe, W | 1 |
Amukoye, E; Bah, B; de Jong, BC; Fielding, K; Gninafon, M; Horton, J; Kassa, F; Lapujade, O; Lienhardt, C; Lo, MB; Merle, CS; Mthiyane, T; N'Diaye, A; Odhiambo, J; Olliaro, PL; Perronne, C; Rustomjee, R; Sismanidis, C; Sow, OB | 1 |
Abena Foe, JL; Aït-Khaled, N; Kuaban, C; Noeske, J; Rieder, HL; Trébucq, A | 1 |
Alvarez-Uria, G; Midde, M | 1 |
Chen, H; Chen, N; Huang, C; Li, Y; Nie, Q; Tang, Q; Tao, L; Wang, X; Wang, Y; Yang, C; Zhou, Y | 1 |
5 review(s) available for gatifloxacin and isoniazid
Article | Year |
---|---|
Tuberculosis: the drug development pipeline at a glance.
Topics: Animals; Antitubercular Agents; Clinical Trials as Topic; Drug Discovery; Humans; Tuberculosis | 2012 |
Isoniazid derivatives and their anti-tubercular activity.
Topics: Animals; Antitubercular Agents; Drug Discovery; Humans; Isoniazid; Mycobacterium tuberculosis; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2017 |
Fluoroquinolone derivatives and their anti-tubercular activities.
Topics: Animals; Antitubercular Agents; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Tuberculosis | 2018 |
Fluoroquinolone-isatin hybrids and their biological activities.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antineoplastic Agents; Antitubercular Agents; Antiviral Agents; Fluoroquinolones; Humans; Isatin; Structure-Activity Relationship | 2019 |
An appraisal of anti-mycobacterial activity with structure-activity relationship of piperazine and its analogues: A review.
Topics: Animals; Antitubercular Agents; Drug Design; Drug Discovery; Humans; Mycobacterium tuberculosis; Piperazine; Structure-Activity Relationship; Tuberculosis | 2021 |
5 trial(s) available for gatifloxacin and isoniazid
Article | Year |
---|---|
Short-course treatment regimen to identify potential antituberculous agents in a murine model of tuberculosis.
Topics: Acetamides; Animals; Antitubercular Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Female; Fluoroquinolones; Gatifloxacin; Isoniazid; Linezolid; Mice; Mice, Inbred C57BL; Oxazolidinones; Rifampin; Time Factors; Tuberculosis | 2004 |
A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Drug Therapy, Combination; Female; Fluoroquinolones; Gatifloxacin; Humans; Isoniazid; Male; Middle Aged; Moxifloxacin; Nonlinear Dynamics; Ofloxacin; Pyrazinamide; Quinolines; Rifampin; Sputum | 2008 |
Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Ciprofloxacin; Ethambutol; Female; Fluoroquinolones; Gatifloxacin; Humans; Injections, Intramuscular; Isoniazid; Levofloxacin; Male; Middle Aged; Multivariate Analysis; Ofloxacin; Pyrazinamide; Rifampin; Streptomycin; Tuberculosis, Meningeal; Young Adult | 2011 |
Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.
Topics: Adult; Antitubercular Agents; Area Under Curve; Coinfection; Drug Administration Schedule; Drug Dosage Calculations; Drug Synergism; Drug Therapy, Combination; Female; Fluoroquinolones; Gatifloxacin; HIV Infections; Humans; Isoniazid; Male; Monte Carlo Method; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary | 2013 |
A four-month gatifloxacin-containing regimen for treating tuberculosis.
Topics: Adult; Antitubercular Agents; Blood Glucose; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Gatifloxacin; Humans; Intention to Treat Analysis; Isoniazid; Male; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary | 2014 |
26 other study(ies) available for gatifloxacin and isoniazid
Article | Year |
---|---|
Discovery of new antitubercular oxazolyl thiosemicarbazones.
Topics: Antibiotics, Antitubercular; Drug Resistance, Multiple, Bacterial; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Structure-Activity Relationship; Thiosemicarbazones | 2006 |
An atom efficient, solvent-free, green synthesis and antimycobacterial evaluation of 2-amino-6-methyl-4-aryl-8-[(E)-arylmethylidene]-5,6,7,8-tetrahydro-4H-pyrano[3,2-c]pyridine-3-carbonitriles.
Topics: Anti-Bacterial Agents; Catalysis; Drug Evaluation, Preclinical; Humans; Microbial Sensitivity Tests; Mycobacterium smegmatis; Nitriles; Pyridines; Solvents | 2007 |
Antimycobacterial activities of novel 1-(cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro- 6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acid.
Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Drug Resistance, Multiple, Bacterial; Female; Light; Mice; Microbial Sensitivity Tests; Mycobacterium smegmatis; Mycobacterium tuberculosis; Naphthyridines; Structure-Activity Relationship; Topoisomerase II Inhibitors; Vero Cells | 2007 |
Synthesis and antimycobacterial evaluation of newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids.
Topics: Amination; Animals; Anti-Bacterial Agents; Cell Survival; Chlorocebus aethiops; Cyclopropanes; DNA Gyrase; Fluorine Compounds; Hydroxyquinolines; Molecular Structure; Mycobacterium; Photosensitizing Agents; Structure-Activity Relationship; Topoisomerase II Inhibitors; Vero Cells | 2008 |
Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo.
Topics: Animals; Antitubercular Agents; Biological Availability; Interferon-gamma; Mice; Mice, Inbred C57BL; Mice, Knockout; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyridones; Quinolones; Treatment Outcome; Tuberculosis, Pulmonary | 2008 |
Antimycobacterial activities of novel 2-(sub)-3-fluoro/nitro-5,12-dihydro-5-oxobenzothiazolo[3,2-a]quinoline-6-carboxylic acid.
Topics: Animals; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Lung; Microbial Sensitivity Tests; Mycobacterium; Mycobacterium smegmatis; Mycobacterium tuberculosis; Quinolines; Spleen; Structure-Activity Relationship | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Synthesis and antimycobacterial activities of novel 6-nitroquinolone-3-carboxylic acids.
Topics: Animals; Anti-Bacterial Agents; Carboxylic Acids; Chlorocebus aethiops; DNA Gyrase; Lung Diseases; Mice; Microbial Sensitivity Tests; Mycobacterium smegmatis; Mycobacterium tuberculosis; Quinolines; Splenic Diseases; Structure-Activity Relationship; Vero Cells | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
Topics: Antitubercular Agents; DNA Gyrase; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Quinolones; Thiazoles; Topoisomerase II Inhibitors; Tuberculosis | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Synthesis and biological evaluation of moxifloxacin-acetyl-1,2,3-1H-triazole-methylene-isatin hybrids as potential anti-tubercular agents against both drug-susceptible and drug-resistant Mycobacterium tuberculosis strains.
Topics: Animals; Antitubercular Agents; Cell Survival; Chlorocebus aethiops; CHO Cells; Cricetulus; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Female; Isatin; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Mycobacterium tuberculosis; Structure-Activity Relationship; Triazoles; Vero Cells | 2019 |
In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.
Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Drug Combinations; Female; Fluoroquinolones; Gatifloxacin; Humans; Isoniazid; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Nasal Cavity; Quinolines; Tuberculosis | 2002 |
Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Fluoroquinolones; Gatifloxacin; Isoniazid; Mycobacterium tuberculosis; Rifampin | 2005 |
Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Drug Synergism; Fluoroquinolones; Gatifloxacin; Hydrogen-Ion Concentration; Isoniazid; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Time Factors | 2006 |
Gatifloxacin in combination with rifampicin in a murine tuberculosis model.
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Drug Combinations; Female; Fluoroquinolones; Gatifloxacin; Isoniazid; Lung; Mice; Mice, Inbred C57BL; Mycobacterium tuberculosis; Rifampin; Tuberculosis | 2007 |
Elevated gatifloxacin and reduced rifampicin concentrations in a single-dose interaction study amongst healthy volunteers.
Topics: Aged; Antibiotics, Antitubercular; Area Under Curve; Cross-Over Studies; Drug Interactions; Female; Fluoroquinolones; Gatifloxacin; Humans; Isoniazid; Male; Middle Aged; Pyrazinamide; Rifampin | 2007 |
Cerebral vacuolation induced in rats by the administration of LUP-3FDC, an anti-tuberculosis cocktail.
Topics: Administration, Oral; Animals; Antitubercular Agents; Cerebral Cortex; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluoroquinolones; Gatifloxacin; Isoniazid; Male; Microscopy, Electron; Pyrazinamide; Rats; Rats, Wistar; Rifampin; Toxicity Tests, Chronic; Ultrasonography; Vacuoles | 2008 |
A short-term model for preliminary screening of potential anti-tubercular compounds.
Topics: Animals; Antitubercular Agents; Colony Count, Microbial; Disease Models, Animal; Drug Discovery; Female; Fluoroquinolones; Gatifloxacin; Isoniazid; Lung; Male; Mice; Mycobacterium Infections; Mycobacterium smegmatis; Mycobacterium tuberculosis; Rifampin; Spleen | 2009 |
Simultaneous determination of isoniazid, rifampicin, levofloxacin in mouse tissues and plasma by high performance liquid chromatography-tandem mass spectrometry.
Topics: Animals; Antibiotics, Antitubercular; Brain Chemistry; Chromatography, High Pressure Liquid; Female; Fluoroquinolones; Gatifloxacin; Intestine, Small; Isoniazid; Kidney; Least-Squares Analysis; Levofloxacin; Liver; Lung; Male; Methanol; Mice; Ofloxacin; Reproducibility of Results; Rifampin; Sensitivity and Specificity; Tandem Mass Spectrometry; Tissue Distribution | 2010 |
High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Cameroon; Clofazimine; Cohort Studies; Confidence Intervals; Developing Countries; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Ethambutol; Female; Fluoroquinolones; Gatifloxacin; Humans; Isoniazid; Kanamycin; Male; Medication Adherence; Middle Aged; Odds Ratio; Prospective Studies; Prothionamide; Pyrazinamide; Risk Assessment; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult | 2015 |
Sex differences and factors influencing the duration of the QT interval in patients on anti-tuberculosis therapy.
Topics: Antitubercular Agents; Clinical Trials as Topic; Electrocardiography; Ethambutol; Female; Gatifloxacin; Heart Rate; Humans; Isoniazid; Male; Models, Theoretical; Multivariate Analysis; Pyrazinamide; Rifampin; Sex Factors; Tuberculosis | 2018 |
High-dose gatifloxacin-based shorter treatment regimens for MDR/RR-TB.
Topics: Antitubercular Agents; Gatifloxacin; Humans; Isoniazid; Pyrazinamide; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2022 |